Harvard Bioscience Inc (HBIO) financials · rev $86.5M
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
Harvard Bioscience Inc (HBIO) rev $86.5M.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $86.5M | $94.1M |
| Cost of Revenue | $36.6M | $39.4M |
| Gross Profit | $49.9M | $54.8M |
| Operating Income | -$48.6M | -$6.21M |
| Net Income | -$56.7M | -$12.4M |
| EPS (Diluted) | -$1.28 | -$0.28 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $80.1M | $126.6M |
| Current Assets | $48.2M | $45.1M |
| Cash & Equivalents | $8.61M | $4.11M |
| Inventory | $20.8M | $23.2M |
| PP&E | $4.79M | $5.11M |
| Total Liabilities | $66.3M | $63.3M |
| Current Liabilities | $22.0M | $55.0M |
| Short-term Debt | N/A | $37.4M |
| Long-term Debt | $35.9M | N/A |
| Total Debt | $35.9M† | $37.4M† |
| Shareholders' Equity | $13.7M | $63.3M |
| Retained Earnings | -$214.7M | -$158.0M |
† Total Debt: Derived: short-term debt plus long-term debt (no total debt stored).
| Line | FY2025 | FY2024 |
|---|---|---|
| Operating Cash Flow | $6.73M | $1.44M |
| CapEx | $1.26M | $2.64M |
| Investing Cash Flow | -$1.86M | -$1.34M |
| Financing Cash Flow | -$1.29M | -$131.0K |
| Net Change in Cash | $4.51M | -$175.0K |
| Free Cash Flow | $5.47M | -$1.20M |
FAQ
What is HBIO P/E and revenue?
Harvard Bioscience Inc (HBIO) rev $86.5M.
What is HBIO revenue?
Harvard Bioscience Inc last cached revenue is $86.5M (FY2025).
Is HBIO profitable?
Harvard Bioscience Inc last cached net income is -$56.7M (FY2025).
What are HBIO total assets?
Harvard Bioscience Inc last cached total assets are $80.1M (FY2025).
What is HBIO free cash flow?
Harvard Bioscience Inc last cached free cash flow is $5.47M (FY2025).
Not investment advice. Cached statements, not a live tape.